Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways

Cardiovascular Research

Volumn 97, Issue 1, 2013, Pages 77-87

  Ma, Jian ^a,b   Wang, Yanpeng ^a,b   Zheng, Dong ^c   Wei, Meng ^a   Xu, Huaxi ^c   Peng, Tianqing ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c JIANGSU UNIVERSITY   (China)

Author keywords

Cardiotoxicity; Doxorubicin; HDAC; p53; Rac1

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; CASPASE 3; DOXORUBICIN; HISTONE DEACETYLASE; HISTONE H2AX; PROTEIN P53; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRICHOSTATIN A;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL DEATH; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVATION; GENE DELETION; HEART FUNCTION; HEART MUSCLE CELL; HISTONE PHOSPHORYLATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETYLATION; ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; DOXORUBICIN; ENZYME ACTIVATION; ENZYME INHIBITORS; FREE RADICAL SCAVENGERS; HEART DISEASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; NADPH OXIDASE; NEUROPEPTIDES; OXIDATIVE STRESS; PHOSPHORYLATION; RAC GTP-BINDING PROTEINS; RAC1 GTP-BINDING PROTEIN; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84871729133     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs309     Document Type: Article

References (44)

1. Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in meta-static breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs 2011;71:2531-2558.
2. Cortes-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 2007;7:56-60. (Pubitemid 47339867)
3. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229. (Pubitemid 38720829)
4. Singal PK, Siveski-Iliskovic N, Kaul N, Sahai M. Significance of adaptation mechanisms in adriamycin induced congestive heart failure. Basic Res Cardiol 1992;87:512-518. (Pubitemid 23007997)
5. Chatterjee K, Zhang J, Honbo N, KarlinerJS. Doxorubicin cardiomyopathy. Cardiology 2010;115:155-162.
6. Miyata S, Takemura G, Kosai K, Takahashi T, Esaki M, Li L et al. Anti-Fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis. Am J Pathol 2010;176:687-698.
7. Yoshida M, Shiojima I, Ikeda H, Komuro I. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 2009;47:698-705.
8. Maruyama S, Shibata R, Ohashi K, Ohashi T, Daida H, Walsh K et al. Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism. J Biol Chem 2011;286:32790-32800.
9. Fan GC, Zhou X, Wang X, Song G, Qian J, Nicolaou P et al. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. Circ Res 2008;103:1270-1279.
10. Kang YJ, Zhou ZX, Wang GW, Buridi A, Klein JB. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases.J Biol Chem 2000;275:13690-13698. (Pubitemid 30257439)
11. Thandavarayan RA, Watanabe K, Sari FR, Ma M, Lakshmanan AP, Giridharan VV et al. Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38alpha mitogen-activated protein kinase mice. Free Radic Biol Med 2010;49:1422-1431.
12. Park AM, Nagase H, Liu L, Vinod Kumar S, Szwergold N, Wong CM et al. Mechanism of anthracycline-mediated down-regulation of GATA4 in the heart. Cardiovasc Res. 2011;90:97-104.
13. Bernuzzi F, Recalcati S, Alberghini A, Cairo G. Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 down-modulation. Chem Biol Interact 2009;177:12-20.
14. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009;61:154-171.
15. Wu X, Hasinoff BB. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs 2005;16:93-99.
16. Zhang YW, Shi J, Li YJ, Wei L Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009;57:435-445.
17. Gilleron M, Marechal X, Montaigne D, Franczak J, Neviere R, Lancel S. NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun 2009;388:727-731.
18. Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, Shah AM et al. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res 2010;70:9287-9297.
19. Sumimoto H, Miyano K, Takeya R. Molecular composition and regulation of the Nox family NAD(P)H oxidases. Biochem Biophys Res Commun 2005;338:677-686. (Pubitemid 41540615)
20. Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J 2008;275:3249-3277. (Pubitemid 351813551)
21. Hordijk PL. Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 2006; 98:453-462.
22. Huelsenbeck J, Henninger C, Schad A, Lackner KJ, Kaina B, Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracycline- induced cardiac toxicity. Cell Death Dis 2011;2:e190.
23. Wolffe AP. Histone deacetylase: a regulator of transcription. Science 1996;272:371-372. (Pubitemid 26138173)
24. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000;275: 20436-20443. (Pubitemid 30457621)
25. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isono M et al. Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med 2006;40:2175-2182. (Pubitemid 43903102)
26. Zhang C, Feng Y, Qu S, Wei X, Zhu H, Luo Q et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res 2011;90:538-545.
27. Yuan F, Xie Q, Wu J, Bai Y, Mao B, Dong Y et al. MST1 promotes apoptosis through regulating Sirt1-dependent p53 deacetylation. J Biol Chem 2011;286:6940-6945.
28. Schmeck B, Beermann W, N'Guessan PD, Hocke AC, Opitz B, Eitel J et al. Simvastatin reduces Chlamydophila pneumoniae-mediated histone modifications and gene expression in cultured human endothelial cells. Circ Res 2008;102:888-895. (Pubitemid 351591545)
29. Shen E, Li Y, Li Y, Shan L, Zhu H, Feng Q et al. Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes 2009;58:2386-2395.
30. Zhu H, Yang Y, Wang Y, Li J, Schiller PW, Peng T. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc Res 2011;92:75-84.
31. Subauste MC, Von Herrath M, Benard V, Chamberlain CE, Chuang TH, Chu K et al. Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. J Biol Chem 2000;275:9725-9733. (Pubitemid 30185206)
32. Zhu H, Shan L, Schiller PW, Mai A, Peng T. Histone deacetylase-3 activation promotes tumor necrosis factor-alpha (TNF-alpha) expression in cardiomyocytes during lipopolysaccharide stimulation. J Biol Chem 2010;285:9429-9436.
33. Li J, Zhu H, Shen E, Wan L, Arnold JM, Peng T. Deficiency of rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. Diabetes 2010;59: 2033-2042.
34. Hamer G, Roepers-Gajadien HL, van Duyn-Goedhart A, Gademan IS, Kal HB, van Buul PP et al. DNA double-strand breaks and gamma-H2AX signaling in the testis. Biol Reprod 2003;68:628-634. (Pubitemid 36139330)
35. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A 2006; 103:7432-7437. (Pubitemid 43727850)
36. Kim DH, Kundu JK, Surh YJ. Redox modulation of p53: mechanisms and functional significance. Mol Carcinog 2011;50:222-234.
37. Sluss HK, Davis RJ. H2AX is a target of the JNK signaling pathway that is required for apoptotic DNA fragmentation. Molecular Cell 2006;23:152-153. (Pubitemid 44062374)
38. Grossman SR. p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 2001;268:2773-2778. (Pubitemid 32862958)
39. Ito A, Lai C-H, Zhao X, Saito Si, Hamilton MH, Appella E et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001;20:1331-1340. (Pubitemid 32233973)
40. Jin Y, Zeng SX, Dai MS, Yang XJ, Lu H. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J Biol Chem 2002;277: 30838-30843. (Pubitemid 34970783)
41. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595-606. (Pubitemid 27357952)
42. Chao C, Wu Z, Mazur SJ, Borges H, Rossi M, Lin T et al. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol 2006;26:6859-6869. (Pubitemid 44387635)
43. Kawano T, Akiyama M, Agawa-Ohta M, Mikami-Terao Y, Iwase S, Yanagisawa T et al. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylationphosphorylation. Int J Oncol 2010;37:787-795.
44. Vahtola E, Louhelainen M, Forsten H, Merasto S, Raivio J, Kaheinen P et al. Sirtuin1-p53, forkhead box O3a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic Goto-Kakizaki rat. Cardiovasc Diabetol 2010;9:5.